The Cancer Letter

Inside information on cancer research and drug development

Vol.
32
No.
7
July 31, 2009Jul 31, 2009
Free
DOWNLOAD THE PDF

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer

Shorter, Simpler Consent Form Proposed For Phase I Trials

How Much Is Life Worth? The $440 Billion Question

Sunitinib Prolongs Survival In Poor Prognosis, Study Finds

Breast MRI Recipients More Likely To Choose Mastectomy

Opioid Pain Reliever Approved With Risk Reduction Plan

NCI Cooperative Group Clinical Trials Approved

Login

Looking for IP Login?